NHS England has declared a pause on new prescriptions of cross-sex hormones for 16 and 17-year-olds questioning their gender identity, following a comprehensive review that found previous research into the drugs’ safety and effectiveness was inadequate. The decision, which comes into force right away, comes after an independent evidence review ordered by the health service determined there was insufficient high-quality evidence to determine whether the hormones help or damage young people. Teenagers already receiving the treatment will continue their prescriptions, though clinicians will be asked to review their cases. NHS England said a small number of teenagers would be affected by the pause and will be offered other treatment options at three gender clinics operated by the NHS for children operating across England.
The Decision and Its Scope
The pause reflects a major change in NHS England’s handling of medical care for gender affirmation for teenagers. Cross-sex hormones, which enable people develop bodily features linked to their desired gender, can result in irreversible changes including a deeper voice, chest development, or other lasting changes. The decision to stop fresh prescriptions stems from the NHS’s assessment that existing evidence cannot clearly demonstrate whether these treatments help or harm young people suffering from gender distress. Professor James Palmer, National Medical Director for Specialised Services at NHS England, highlighted that the review had been “remarkably comprehensive and complex,” ultimately determining that existing evidence fails to support ongoing use of hormones that masculinise or feminise for young people under 18.
NHS England has launched a 90-day consultation process starting Monday to collect additional feedback on the revised policy and review results. The health service expects this consultation process will uncover any data that could have been missed during the original review. Existing guidance already prohibited prescriptions for under-16s requesting gender-related treatment, so the new pause essentially broadens restrictions to cover 16 and 17-year-olds. The NHS stressed its commitment to providing full support, stating that young people who cannot receive hormone therapy will be offered alternative forms of care through its three dedicated gender clinics for children across England.
- Pause covers initial prescriptions for adolescents aged 16-17 only
- Young people already on hormones will proceed with ongoing treatment
- Clinicians will examine active cases for ongoing suitability
- Alternative care accessible at three NHS gender clinics throughout England
Evidence Assessment Results
The choice to suspend hormone prescriptions originates from a thorough evidence assessment commissioned by NHS England, which examined the scientific foundation for cross-sex hormone treatment in adolescents. The review, consisting of ten independent assessments of different aspects of testosterone and oestrogen use, uncovered significant gaps in the evidence supporting existing clinical practice. NHS England concluded that the available evidence was insufficient to establish whether these therapies benefit or harm adolescents experiencing gender dysphoria, making it impossible to support the continuation of new prescriptions with confidence in their safety and efficacy.
This observation supports concerns raised in Dr Hilary Cass’s significant April 2024 report on pediatric gender care, which emphasized “notably insufficient” data regarding clinical treatments in this area. The Cass report encouraged NHS England to conduct its own detailed examination of the evidence base. The emerging assessment focused on various outcomes for young patients, including life quality, mental health, and general wellbeing. Rather than waiting for further evidence to surface, NHS England opted to adopt a cautious strategy, pausing novel prescriptions while continuing to assess responses from campaigning organizations and healthcare professionals.
Study Results
The ten independent evidence reviews examined the effects of hormone hormones covering physical and mental outcomes for young people identifying as a different gender from their biological sex. Researchers assessed existing literature on the way such therapies affected quality of life, mental health status, and gender-related distress in young people. The review was intentionally thorough, seeking to leave no stone unturned in evaluating whether adequate evidence was available to justify ongoing prescription for individuals under 18 years old.
The overarching conclusion was definitive: the available evidence did not meet the threshold needed to with certainty endorse hormone treatment for this population. Professor Palmer indicated that the review “showed that the available evidence does not support the continued use of masculinising or feminising hormones” to treat young people under 18 with gender dysphoria or gender incongruence. This conclusion implied NHS England could not determine whether the treatments were safe or efficacious, calling for a halt subject to further clarification and professional consultation.
- Ten independent reviews assessed different aspects of hormonal therapy
- Research assessed wellbeing and mental health outcomes
- Available evidence deemed inadequate to support ongoing treatment
- Cannot determine if treatments harm or help young people
Public Response and Legal Battles
The NHS choice to pause hormone prescriptions has triggered rapid and divided responses from across the healthcare and advocacy sectors. Trans advocacy groups have expressed strong opposition to the policy change, with some organisations signalling their intention to take legal proceedings against NHS England. These groups contend that the pause restricts access to potentially life-changing treatment for young people with gender dysphoria, and maintain that the evidence review does not justify such a limiting stance. The consultation period beginning Monday will be crucial in determining whether NHS England’s position evolves or hardens based on stakeholder feedback.
Healthcare professionals working in gender identity programs have also commented on the decision, with views extending across cautious support to significant concern. Some healthcare providers welcome the evidence assessment as a required action to verify treatments are sufficiently evidence-based, while others are concerned that the pause may damage vulnerable young people who have commenced hormone therapy or are seeking to obtain care. The 90-day engagement window serves as an opportunity for these different stakeholders to formally present their perspectives, conceivably shaping whether the temporary pause transforms into permanent policy or is adjusted based on new evidence or professional consensus.
| Group | Position |
|---|---|
| Trans Advocacy Organisations | Opposing the pause; considering legal action against NHS England |
| Some Healthcare Professionals | Supporting cautious approach; welcoming evidence-based review |
| Other Clinicians | Concerned about harm to young people already in treatment |
| NHS England Leadership | Defending precautionary approach; seeking further consultation |
Advocacy Coalition Response
Trans advocacy organisations have objected to the NHS pause as discriminatory and possibly injurious to at-risk adolescents. These groups argue that the determination to suspend fresh prescriptions runs counter to the experiences of transgender adolescents who describe enhanced mental wellbeing and quality of life following hormone treatment. They contend that the evidence review’s conclusion of “weak evidence” does not justify such a restrictive policy, and that the pause essentially prevents care to people with the greatest need while pending complete scientific confirmation that may never materialise.
Lawsuits seem probable, with civil rights organisations stating they intend to seek judicial intervention to overturn or modify the medication freeze. These groups maintain that the decision infringes upon the rights of youth to access appropriate medical care and could amount to prejudice toward gender identification. They stress that individual clinical assessments should determine treatment access rather than universal prohibitions, and that the discussion phase should carefully examine testimony from trans individuals themselves about direct experiences with hormonal treatment.
Commercial Sector and Global Framework
While NHS England implements its conservative approach, the private medical industry in the UK maintains availability of hormone treatments to teenagers outside the public health system. This results in a two-tier system where higher-income families may receive treatments that the NHS has put on hold, generating questions about fairness and availability. The difference between NHS policy and private provision underscores fundamental issues about how evidence-based recommendations should work across various healthcare environments, and whether teenagers’ ability to access to gender-affirming care should rest on their household income rather than clinical need.
Internationally, healthcare systems have implemented varying approaches to hormone treatment for young people questioning their gender. Some European countries, including Sweden and Finland, have likewise restricted restrictions on cross-sex hormones for minors in recent years, pointing to a lack of evidence. Conversely, other nations uphold more permissive treatment guidelines, with some medical organisations contending that withholding care results in greater psychological harm. These divergent international responses underscore the genuine scientific uncertainty regarding the long-term effects and benefits of these interventions, and suggest that consensus has not yet emerged among global medical authorities on the suitable course of treatment for adolescents with gender dysphoria.
- Private clinics in the UK persist in providing hormonal therapy to adolescents in spite of NHS pause
- Finland and Sweden have similarly restricted hormone prescriptions for minors in the past few years
- International medical organisations continue to disagree on suitable therapeutic approaches for adolescents
What’s Next
NHS England has initiated a formal framework to determine its long-term policy on hormonal therapy for adolescents exploring their gender identity. A 90-day public consultation started on Monday will gather feedback from advocacy groups, healthcare professionals, and the broader community on the research conclusions and updated recommendations. The health service has stressed that this feedback phase is vital for finding any data not captured in the first assessment during the first review stage. The outcomes will influence whether the present suspension on novel treatments becomes permanent policy or whether treatment restarts under revised parameters.
During the assessment window, NHS England will continue to monitor and support young people already receiving hormone treatment, with clinicians performing individual assessments of each patient’s care plan. The three existing NHS gender clinics for children will expand their provision of alternative care options for those without access to hormones, including psychological support and counselling services. Following the 90-day period, NHS England will analyse all feedback received and reach a final determination regarding longer-term guidance. This decision will have major consequences for many young people across England pursuing gender-affirming treatment.
The 90-Day Consultation Process
The consultation represents a official chance for stakeholders to support or challenge NHS England’s preliminary findings. Campaign organisations, healthcare practitioners, and members of the general public can submit evidence and perspectives on whether the review correctly represents current scientific understanding. Trans advocacy organisations have already indicated they may take legal action, indicating the consultation will be contentious. NHS England has stated it will carefully review all responses, specifically aiming to find any robust evidence that the initial review may have missed or underweighted in its analysis.
The 90-day window is created to balance the requirement for comprehensive deliberation with the pressing need of providing transparency to youth and healthcare providers presently unclear about treatment availability. NHS England will gather and analyse all submissions before releasing its final decision on revised guidance. This extended period allows clinicians to express clinical experiences, research organizations to provide further data, and youth in their own right to describe how the new policies impact their overall health and wellbeing.